{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T03:30:44Z","timestamp":1790307044083,"version":"4.1.0"},"reference-count":7,"publisher":"BMJ","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.bmj.com\/company\/legal-information\/terms-conditions\/legal-information\/tdm-licencepolicy"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ"],"DOI":"10.1136\/bmj-2026-100870","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T15:35:11Z","timestamp":1790177711000},"page":"e100870","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Daraxonrasib: How soon could the new drug for pancreatic cancer be available in the UK?"],"prefix":"10.1136","volume":"394","author":[{"given":"Katharine","family":"Lang","sequence":"first","affiliation":[{"name":"Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"key":"2026092312101407000_394.sep23_8.e100870.1","unstructured":"Cancer Research UK. Survival for pancreatic cancer. Sep 2026. https:\/\/www.cancerresearchuk.org\/about-cancer\/pancreatic-cancer\/survival."},{"key":"2026092312101407000_394.sep23_8.e100870.2","unstructured":"Food and Drug Administration. FDA approves first in class targeted therapy for metastatic pancreatic cancer. 26 Aug 2026. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-class-targeted-therapy-metastatic-pancreatic-cancer"},{"key":"2026092312101407000_394.sep23_8.e100870.3","doi-asserted-by":"publisher","DOI":"10.3390\/molecules30163436"},{"key":"2026092312101407000_394.sep23_8.e100870.4","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2013.410"},{"key":"2026092312101407000_394.sep23_8.e100870.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2605555"},{"key":"2026092312101407000_394.sep23_8.e100870.6","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2026-902114"},{"key":"2026092312101407000_394.sep23_8.e100870.7","unstructured":"A $480 000-a-year pill reflects a new normal for cancer drugs. New York Times. 31 Aug 2026. https:\/\/www.nytimes.com\/2026\/08\/31\/business\/pancreatic-cancer-drug-prices.html"}],"container-title":["BMJ"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/data.bmj.org\/tdm\/10.1136\/bmj-2026-100870","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmj-2026-100870","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:10:22Z","timestamp":1790190622000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.bmj.com\/lookup\/doi\/10.1136\/bmj-2026-100870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":7,"alternative-id":["10.1136\/bmj-2026-100870"],"URL":"https:\/\/doi.org\/10.1136\/bmj-2026-100870","relation":{},"ISSN":["1756-1833"],"issn-type":[{"value":"1756-1833","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]}}}